64
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Amisulpride in the treatment of somatoform disorders

, &
Pages 792-793 | Published online: 03 Sep 2011

References

  • Rief W, Barsky AJ. Psychobiological perspectives on somatoform disorders. Psychoneuroendocrinology 2005; 30:996–1002.
  • Rouillon F, Rahola G, Van Moffaert M . Sulpiride in the treatment of somatoform disorders: results of a European observational study to characterize the responder profile. J Int Med Research 2001; 29:304–313.
  • Rapps N, van Oudenhove L, Enck P, Aziz Q. Brain imaging of visceral functions in healthy volunteers and IBS patients. J Psychosom Res 2008; 64:599–604.
  • Singer T, Seymour B, O'Doherty JP, Stephan KE, Dolan RJ, Frith CD. Empathic neural responses are modulated by the perceived fairness of others. Nature 2006; 439:466–469.
  • Rocca P, Fonzo V, Ravizza L . A comparison of paroxetine and amisulpride in the treatment of dysthymic disorder. J Affect Disord 2002; 70:313–317.
  • Vaiva G, Thomas P, Llorca PM . SPECT imaging, clinical features, and cognition before and after low doses of amisulpride in schizophrenic patients with the deficit syndrome. Psychiatry Res 2002; 115:37–48.
  • Abbas AI, Hedlund PB, Huang XP, Tran TB, Meltzer HY, Roth BL. Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo. Psychopharmacology (Berl) 2009; 205:119–128.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.